Explore symptoms, assessment and rehabilitation considerations for osteoporosis.
If you take semaglutide and are concerned about osteoporosis, discuss bone health alongside the reason for your prescription. A bone-density result, an exercise programme and a medicine decision answer different questions. Your fracture history and wider health are part of that discussion.
Ozempic and semaglutide: check the prescribed product
Ozempic contains semaglutide. The manufacturer's linked US prescribing information lists type 2 diabetes-related indications. Semaglutide is also used in weight-management care, but products and approved uses vary. Ask your prescriber why your particular product was chosen and what follow-up you need. Do not change prescribed treatment based on a general bone-health article.
What does the semaglutide bone study show?
A 2024 randomized trial compared weekly semaglutide with placebo in 64 adults already at increased fracture risk, mostly postmenopausal women. After 52 weeks, the semaglutide group had lower bone density at the lumbar spine and total hip than the placebo group. The primary bone-formation marker did not improve, and body weight also fell.
This small study focused on bone markers and density, rather than proving an increase in fracture events. It cannot predict your individual risk or establish that every person taking Ozempic develops osteoporosis. Use the finding to discuss appropriate assessment with your prescriber, especially if you already have bone-health concerns.
Assess fracture risk, not just one scan number
The NHS osteoporosis overview explains that osteoporosis weakens bones and may first be identified after a fracture. Assessment can combine risk factors with a DXA bone-density scan when appropriate. Having a semaglutide prescription alone is not a complete bone-risk assessment.
- Tell your clinician about previous fractures and how they happened.
- Describe falls, balance concerns and changes in everyday mobility.
- Bring previous scan reports and a list of medicines and supplements.
- Discuss weight changes and any difficulty eating adequately.
- Ask whether testing would change the care plan and when to review it.
Understanding T-scores and Z-scores on a DXA report
A T-score compares bone density with a young-adult reference. The ISCD adult positions prefer T-scores for postmenopausal women and men aged 50 or older. Z-scores are generally preferred before menopause and for men younger than 50, so the same T-score categories should not be applied to every person.
Where T-score classification applies, NIAMS explains these categories:
- −1.0 or higher: Normal bone-density category.
- Below −1.0 and above −2.5: Low bone mass, also called osteopenia.
- −2.5 or lower: Osteoporosis range at an appropriate measurement site.
Your clinician should interpret the measured sites and results with fracture history and other risks. A scan does not guarantee that you will or will not break a bone, and a category alone does not select an exercise intensity or medicine.
Exercise supports care but does not guarantee prevention
The Royal Osteoporosis Society exercise guide discusses impact and resistance exercise to support bone strength. Activity should match your ability and be built up gradually. Exercise complements appropriate osteoporosis medicine; it does not replace it or promise to prevent all bone loss.
Its exercise-safety guidance recommends individual advice when recovering from a fracture, after spinal or multiple fractures, or when other concerns affect movement. Some impact or bending exercises need adaptation. Ask what is appropriate before following a generic gym or home routine.
For older adults with assessed walking or balance difficulties, FitMe's geriatric physiotherapy service may help address movement goals alongside medical bone-health care. Our physiotherapy for seniors guide explains preparing for assessment and choosing practical goals.
Can a vibration plate treat osteoporosis?
The Royal Osteoporosis Society vibration review describes uncertain evidence for stronger bones or fewer fractures in people with osteoporosis. Whole-body vibration may help strength or balance for some people, but this does not establish it as a replacement for osteoporosis treatment.
Devices and vibration intensity differ, and suitability depends on your health and fracture history. Discuss those details with a qualified clinician before buying or using a plate. This guide cannot prescribe a device setting or assure a bone-density benefit.
New pain and symptoms needing urgent assessment
New pain after a fall or a minor injury warrants assessment if you are concerned about a fracture. Our fracture guide explains injury symptoms and protection while arranging care.
The NHS back pain guidance advises urgent help for sudden severe or rapidly worsening back pain. Bladder or bowel changes, loss of feeling around the genitals or anus, or symptoms in both legs with back pain need emergency assessment.
Bring your prescription details and scan reports to follow-up. Review nutrition, movement, falls and any medical treatment together, rather than using an exercise or vibration programme as proof that bone health is protected.
Sources and further reading
- Novo Nordisk: US Ozempic prescribing information, revised May 2026
- eClinicalMedicine 2024: semaglutide trial in adults at increased fracture risk
- NHS: osteoporosis, fracture-risk assessment and treatment
- ISCD: adult bone-density interpretation and T-score versus Z-score use
- NIAMS: bone-density test results and T-score categories
- Royal Osteoporosis Society: exercise for bone strength and the role of medicines
- Royal Osteoporosis Society: exercising safely with osteoporosis and fractures
- Royal Osteoporosis Society: vibration therapy evidence and suitability
- NHS: back pain, self-care and urgent symptoms
Need a Personalized Recovery Plan?
A physiotherapist can help you choose exercises and adjust activity to your circumstances. Explore our physiotherapy services, see how our treatment process works, or explore more practical guides in our blog library.



